Home/Investors/BioAdvance

BioAdvance

Biotech Investor · 3 portfolio companies

Portfolio

3

Focus Areas

6

Top Stage

Phase 1

Investment Focus

Mitochondrial Disease Rare Diseases Central Nervous System (CNS) Disorders Opioid Use Disorder Neuropathic Pain Neuroinflammation

Portfolio Companies

Company	Stage	Valuation	Focus
Ribonova	Phase 1	—	Mitochondrial Disease, Rare Diseases
Ossianix	Pre-clinical	—	Central Nervous System (CNS) Disorders
Mebias Discovery	Phase 1	—	Opioid Use Disorder, Neuropathic Pain

Frequent Co-Investors

Life Science Angels1 shared Militia Hill Ventures1 shared National Institute on Drug Abuse (NIDA)1 shared ALS Association1 shared Lundbeck Pharmaceuticals1 shared Viva Biotech (Shanghai) Ltd.1 shared